Swiss National Bank Cuts Stock Position in Bausch Health Companies Inc. (NYSE:BHC)

Swiss National Bank trimmed its position in shares of Bausch Health Companies Inc. (NYSE:BHC) by 5.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 543,860 shares of the company’s stock after selling 32,300 shares during the period. Swiss National Bank owned about 0.15% of Bausch Health Companies worth $4,394,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Tobam grew its position in Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after acquiring an additional 1,422 shares during the last quarter. DGS Capital Management LLC purchased a new stake in shares of Bausch Health Companies in the 4th quarter valued at $143,000. Kendall Capital Management grew its holdings in shares of Bausch Health Companies by 43.4% during the 4th quarter. Kendall Capital Management now owns 17,995 shares of the company’s stock valued at $145,000 after purchasing an additional 5,445 shares during the last quarter. Principal Securities Inc. raised its position in Bausch Health Companies by 39.7% in the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock worth $155,000 after purchasing an additional 5,464 shares during the period. Finally, Aigen Investment Management LP bought a new stake in Bausch Health Companies in the fourth quarter worth $180,000. Institutional investors own 78.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BHC. Royal Bank of Canada decreased their price objective on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Bausch Health Companies currently has a consensus rating of “Hold” and a consensus target price of $7.42.

Bausch Health Companies Stock Performance

Shares of BHC stock opened at $7.03 on Wednesday. The firm has a market cap of $2.59 billion, a P/E ratio of -58.58, a P/E/G ratio of 0.37 and a beta of 0.59. The business’s 50 day moving average price is $7.12 and its 200-day moving average price is $7.72. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The company had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.51 billion. As a group, equities analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.